C L Toze
Overview
Explore the profile of C L Toze including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
306
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shustik C, Bence-Bruckler I, Delage R, Owen C, Toze C, Coutre S
Ann Hematol
. 2017 Apr;
96(7):1185-1196.
PMID: 28389687
Treatment of chronic lymphocytic leukemia (CLL) has advanced with the introduction of chemoimmunotherapy (CIT) agents that have improved the outcomes of frontline therapy. However, most treated patients will relapse and...
2.
Michelis F, Atenafu E, Couban S, Frazer J, Shivakumar S, Hogge D, et al.
Bone Marrow Transplant
. 2016 Mar;
51(7):1019-21.
PMID: 26974273
No abstract available.
3.
Lachance S, Christofides A, Lee J, Sehn L, Ritchie B, Shustik C, et al.
Curr Oncol
. 2016 Mar;
23(1):42-51.
PMID: 26966403
Infections are a major cause of morbidity and mortality in patients with chronic lymphocytic leukemia (cll), who typically have increased susceptibility because of hypogammaglobulinemia (hgg) related to their disease and...
4.
Seftel M, Paulson K, Doocey R, Song K, Czaykowski P, Coppin C, et al.
Bone Marrow Transplant
. 2010 Nov;
46(6):852-7.
PMID: 21042312
Failure of cisplatin-based chemotherapy in advanced germ cell tumour (GCT) is associated with a poor outcome. High-dose chemotherapy and auto-SCT is one therapeutic option, although the long-term outcome after this...
5.
Abou-Mourad Y, Lau B, Barnett M, Forrest D, Hogge D, Nantel S, et al.
Bone Marrow Transplant
. 2009 Jul;
45(2):295-302.
PMID: 19597425
We analyzed the late outcomes of 429 long-term survivors post allogeneic hematopoietic SCT (allo-HSCT) who received transplant in our center between 1981 and 2002, and were free of their primary...
6.
Ramadan K, Connors J, Al-Tourah A, Song K, Gascoyne R, Barnett M, et al.
Bone Marrow Transplant
. 2008 Aug;
42(9):601-8.
PMID: 18695664
Outcome is poor with conventional therapy for relapsed transformed non-Hodgkin's lymphoma (NHL). Autologous SCT has been successfully employed; however the impact of allogeneic SCT has not been well defined. We...
7.
Nevill T, Hogge D, Toze C, Nantel S, Power M, Abou Mourad Y, et al.
Bone Marrow Transplant
. 2008 Aug;
42(10):659-66.
PMID: 18679372
Administration of alkylating agents (Alk), topoisomerase II inhibitors (Topo II) and radiotherapy (RT) can result in therapy-related myelodysplastic syndrome or acute myelogenous leukaemia (t-MDS/t-AML), the optimal treatment for which is...
8.
Halim T, Song K, Barnett M, Forrest D, Hogge D, Nantel S, et al.
Ann Oncol
. 2007 Apr;
18(7):1246-52.
PMID: 17442662
Background: Curative intent chemotherapy for acute myelogenous leukemia (AML) leads to prolonged severe neutropenia, during which patients are highly susceptible to infection. Traditionally these high-risk patients were treated as inpatients....
9.
Song K, Barnett M, Gascoyne R, Chhanabhai M, Forrest D, Hogge D, et al.
Ann Oncol
. 2006 Dec;
18(3):535-40.
PMID: 17158775
Background: Controversy exists regarding the role of high-dose therapy followed by stem-cell transplant (SCT) in the treatment of T-cell lymphoblastic lymphoma (T-LBL). We conducted an intention-to-treat analysis of the strategy...
10.
Greenwood M, Seftel M, Richardson C, Barbaric D, Barnett M, Bruyere H, et al.
Leuk Lymphoma
. 2006 Aug;
47(7):1245-52.
PMID: 16923553
Acute myeloid leukemia (AML) presenting with a high leukocyte count has been associated with an increase in induction mortality and poor results in a number of other survival measures. However,...